CN104024247B - 有用于治疗人类乳头瘤病毒的被胍基取代的聚酰胺 - Google Patents

有用于治疗人类乳头瘤病毒的被胍基取代的聚酰胺 Download PDF

Info

Publication number
CN104024247B
CN104024247B CN201280049712.1A CN201280049712A CN104024247B CN 104024247 B CN104024247 B CN 104024247B CN 201280049712 A CN201280049712 A CN 201280049712A CN 104024247 B CN104024247 B CN 104024247B
Authority
CN
China
Prior art keywords
tmg
polyamide
hpv
pyβpypyβpypypyβpyβ
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280049712.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104024247A (zh
Inventor
詹姆士·K·巴什金
特里·G·爱德华兹
克里斯多夫·费舍尔
小乔治·D·哈里斯
凯文·J·科勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NanoVir LLC
University of Missouri–St. Louis
Original Assignee
NanoVir LLC
University of Missouri–St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NanoVir LLC, University of Missouri–St. Louis filed Critical NanoVir LLC
Publication of CN104024247A publication Critical patent/CN104024247A/zh
Application granted granted Critical
Publication of CN104024247B publication Critical patent/CN104024247B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280049712.1A 2011-10-10 2012-10-10 有用于治疗人类乳头瘤病毒的被胍基取代的聚酰胺 Expired - Fee Related CN104024247B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545311P 2011-10-10 2011-10-10
US61/545,311 2011-10-10
PCT/US2012/059604 WO2013055825A2 (en) 2011-10-10 2012-10-10 Guanidinyl-substituted polyamides useful for treating human papilloma virus

Publications (2)

Publication Number Publication Date
CN104024247A CN104024247A (zh) 2014-09-03
CN104024247B true CN104024247B (zh) 2016-05-25

Family

ID=48042465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049712.1A Expired - Fee Related CN104024247B (zh) 2011-10-10 2012-10-10 有用于治疗人类乳头瘤病毒的被胍基取代的聚酰胺

Country Status (12)

Country Link
US (1) US9133228B2 (enExample)
EP (1) EP2751096A4 (enExample)
JP (1) JP2015502330A (enExample)
KR (1) KR20140074996A (enExample)
CN (1) CN104024247B (enExample)
AU (1) AU2012322835A1 (enExample)
BR (1) BR112014008464A2 (enExample)
CA (1) CA2851516C (enExample)
HK (1) HK1201064A1 (enExample)
RU (1) RU2014113702A (enExample)
SG (1) SG11201401226YA (enExample)
WO (1) WO2013055825A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982020B2 (en) * 2011-10-10 2018-05-29 Nanovir Llc Antiviral compounds and methods for treating infections caused by double-stranded DNA viruses
WO2016022664A1 (en) * 2014-08-05 2016-02-11 Nanovir Llc Antiviral compounds and methods for treating infections caused by double-stranded dna viruses
EP4365590B1 (en) * 2019-03-20 2025-09-24 Juntendo Educational Foundation Agent targeting double-membrane organelle dna

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033282A2 (en) * 2003-10-01 2005-04-14 Pharmacia & Upjohn Company Llc Polyamide compositions and therapeutic methods for treatment of human papilloma virus
WO2007130616A2 (en) * 2006-05-04 2007-11-15 Nanovir, Llc Polyamides for treating human papilloma virus
US20080287318A1 (en) * 2003-12-10 2008-11-20 Wolfgang Kranewitter Primers and Probes for Detecting Genital Hpv Genotypes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004732A1 (en) 1993-08-06 1995-02-16 Synphar Laboratories, Inc. Oligopeptide antiretroviral agents
EP0973740A1 (en) 1996-02-26 2000-01-26 California Institute Of Technology Design, synthesis and use of specific polyamide dna-binding ligands
CN1260006A (zh) 1996-02-26 2000-07-12 加利福尼亚州技术学院 双链dna和杂环低聚物之间复合物的形成
JP2001513759A (ja) 1996-02-26 2001-09-04 カリフォルニア・インスティチュート・オブ・テクノロジー 二本鎖ｄｎａの副溝において結合する改良されたポリアミド
US5998140A (en) 1996-07-31 1999-12-07 The Scripps Research Institute Complex formation between dsDNA and oligomer of cyclic heterocycles
JP2002515057A (ja) 1996-08-01 2002-05-21 カリフォルニア・インスティチュート・オブ・テクノロジー ポリアミドｄｎａ結合リガンドによる遺伝子発現の阻害
AU5910899A (en) 1998-09-11 2000-04-03 California Institute Of Technology Inhibition of oncogene transcription by synthetic polyamides
US6673940B1 (en) 1999-01-08 2004-01-06 California Institute Of Technology Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
JP4012145B2 (ja) 2001-06-25 2007-11-21 独立行政法人科学技術振興機構 ピロール−イミダゾールポリアミドの固相合成法
CA2465886A1 (en) 2001-11-07 2003-05-15 Kathleen S. Crowley Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
CA2466391A1 (en) 2001-11-07 2003-05-15 Dennis P. Phillion Polyamide modulators of cox2 transcription
WO2004064913A1 (en) 2003-01-16 2004-08-05 Femmepharma Holding Company, Inc. Vaginal or rectal applicator
WO2004078943A2 (en) 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
CA2531869A1 (en) 2003-04-30 2004-11-18 Pharmacia Corporation Compounds having a fused, bicyclic moiety for binding to the minor groove of dsdna
US8399013B2 (en) 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
WO2007045096A1 (en) * 2005-10-21 2007-04-26 University Of Saskatchewan Oligoheteroaromatic luminiscent assemblies as high-affinity dna sequence-directed ligands
WO2007103584A2 (en) 2006-03-09 2007-09-13 Nanovir, Llc Polyamides for treating human papilloma virus
US8993609B2 (en) 2006-05-04 2015-03-31 Nanovir, Llc Compounds for treating papilloma virus infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033282A2 (en) * 2003-10-01 2005-04-14 Pharmacia & Upjohn Company Llc Polyamide compositions and therapeutic methods for treatment of human papilloma virus
US20080287318A1 (en) * 2003-12-10 2008-11-20 Wolfgang Kranewitter Primers and Probes for Detecting Genital Hpv Genotypes
WO2007130616A2 (en) * 2006-05-04 2007-11-15 Nanovir, Llc Polyamides for treating human papilloma virus

Also Published As

Publication number Publication date
KR20140074996A (ko) 2014-06-18
US9133228B2 (en) 2015-09-15
WO2013055825A3 (en) 2013-06-13
CN104024247A (zh) 2014-09-03
BR112014008464A2 (pt) 2017-04-11
EP2751096A2 (en) 2014-07-09
NZ623292A (en) 2016-02-26
CA2851516A1 (en) 2013-04-18
EP2751096A4 (en) 2015-04-08
AU2012322835A1 (en) 2014-04-17
RU2014113702A (ru) 2015-11-20
WO2013055825A2 (en) 2013-04-18
US20130090362A1 (en) 2013-04-11
JP2015502330A (ja) 2015-01-22
HK1201064A1 (en) 2015-08-21
SG11201401226YA (en) 2014-05-29
CA2851516C (en) 2016-08-02

Similar Documents

Publication Publication Date Title
JP5796039B2 (ja) ヒトパピローマウイルスを処置するためのポリアミド類
JP3326181B2 (ja) 連結ペプチド核酸
CN118477088A (zh) N4-羟基胞苷及衍生物和与其相关的抗病毒用途
WO2007103584A2 (en) Polyamides for treating human papilloma virus
WO2005033282A2 (en) Polyamide compositions and therapeutic methods for treatment of human papilloma virus
US9290551B2 (en) Compounds for treating papilloma virus infection
CN104024247A (zh) 有用于治疗人类乳头瘤病毒的被胍基取代的聚酰胺
US9982020B2 (en) Antiviral compounds and methods for treating infections caused by double-stranded DNA viruses
JP2877910B2 (ja) ２―オキソアルキル側鎖を有する抗ウイルスペプチド
JP2877908B2 (ja) 抗ヘルペスペンタペプチド類
NZ623292B2 (en) Guanidinyl-substituted polyamides useful for treating human papilloma virus
WO2016022664A1 (en) Antiviral compounds and methods for treating infections caused by double-stranded dna viruses
Bashkin et al. Polyamides containing amino butyric acid-based building blocks
Bashkin et al. Polyamides for treating human papilloma virus
JP2011503224A (ja) 新規なヒトパピローマウイルス阻害剤およびそれを含有する医薬組成物
WO2015161479A1 (zh) 一种嘧啶类化合物的抗宫颈癌用途
Wilson Emerging therapies for human papillomavirus infection
JP2960350B2 (ja) ヒト免疫不全ウイルスプロテアーゼ阻害剤、製造方法及び組成物
Edwards i, United States Patent (10) Patent No.: US 9.333. 232 B2
Nanovir Bashkin et al.(43) Pub. Date: Sep. 6, 2012

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201064

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160525

Termination date: 20161010

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201064

Country of ref document: HK